Eupraxia Pharmaceuticals Files 6-K with Financials
Ticker: EPRX · Form: 6-K · Filed: Aug 7, 2024 · CIK: 1581178
Sentiment: neutral
Topics: financials, filing, sec
TL;DR
Eupraxia dropped its Q2 financials via 6-K, check F-10 and S-8 filings for context.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on August 7, 2024, incorporating by reference its consolidated financial statements for the three and six months ended June 30, 2024, and Management's Discussion and Analysis. These documents are incorporated into their existing Registration Statements on Form F-10 (File No. 333-276586) and Form S-8 (File No. 333-278534).
Why It Matters
This filing provides investors with updated financial performance data for Eupraxia Pharmaceuticals, crucial for assessing the company's current financial health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not introduce new material risks.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- August 7, 2024 (date) — Filing Date
- June 30, 2024 (date) — Financial Period End
- 333-276586 (other) — Form F-10 File Number
- 333-278534 (other) — Form S-8 File Number
FAQ
What period do the incorporated financial statements cover?
The incorporated financial statements cover the three and six months ended June 30, 2024.
What forms are the financial statements incorporated into?
The financial statements are incorporated into Eupraxia Pharmaceuticals' Registration Statement on Form F-10 (File No. 333-276586) and Registration Statement on Form S-8 (File No. 333-278534).
What is the filing type and date?
The filing is a Form 6-K, filed on August 7, 2024.
What are the two main documents included in this 6-K report?
The report includes Exhibit 99.1 (Consolidated Financial Statements) and Exhibit 99.2 (Management's Discussion and Analysis).
Does Eupraxia Pharmaceuticals file under Form 20-F or 40-F annually?
Eupraxia Pharmaceuticals indicates it files under Form 40-F.
Filing Stats: 248 words · 1 min read · ~1 pages · Grade level 9.3 · Accepted 2024-08-07 17:14:29
Filing Documents
- d795649d6k.htm (6-K) — 11KB
- d795649dex991.htm (EX-99.1) — 411KB
- d795649dex992.htm (EX-99.2) — 339KB
- d795649dex993.htm (EX-99.3) — 23KB
- d795649dex994.htm (EX-99.4) — 12KB
- d795649dex995.htm (EX-99.5) — 12KB
- g795649dsp55.jpg (GRAPHIC) — 23KB
- g795649g0803084611256.jpg (GRAPHIC) — 13KB
- 0001193125-24-196031.txt ( ) — 857KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: August 7, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer